MentionFox
Home › Executive changes › Aspire Biopharma Holdings, Inc.
Leadership changes · ASBP · SEC Form 8-K, Item 5.02

Leadership changes at Aspire Biopharma Holdings, Inc. (2026)

Before you join, sell to or invest in Aspire Biopharma Holdings, Inc.

MentionFox check on Aspire Biopharma Holdings, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/aspire-biopharma-holdings

Check Aspire Biopharma Holdings, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Aspire Biopharma Holdings, Inc.?

Who joined and who left Aspire Biopharma Holdings, Inc. (ASBP)? 2 departures reported from 2026-01-13 to 2026-02-12, each cited to the company's own filing.

Donald G. Fell left the role of Director at Aspire Biopharma Holdings, Inc. As of November 14, 2026, Aspire Biopharma Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 13, 2026 to February 12, 2026, naming 2 departures (Form 8-K, February 12, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Highbridge Capital Management, LLC also filed stake reports on 83 other companies ↓

Sell to companies like Aspire Biopharma Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
Out (departing)2
Latest filing2026-02-12

Aspire Biopharma Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-13 to 2026-02-12. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Aspire Biopharma Holdings, Inc. files it.

Also on the record for Aspire Biopharma Holdings, Inc.

DateRecordFigureOur pageSource
November 5, 2026Stake report, Schedule 13G, by Funk, Stephen P.5.8% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Highbridge Capital Management, LLC—5%+ stakesSource
August 10, 2026Stake report, Schedule 13G, by GARY SHIRINYAN7.7% of the class5%+ stakesSource
August 6, 2026Stake report, Schedule 13G/A, by Lance Friedman7.92% of the class5%+ stakesSource
July 2, 2026Stake report, Schedule 13G, by Rubenbauer Alois Ryan III5% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Highbridge Capital Management, LLC5.2% of the class5%+ stakesSource
May 13, 2026Stake report, Schedule 13G/A, by Ardsley Advisory Partners LP—5%+ stakesSource
April 10, 2026IPO filing, Form S-1/A—IPO filingsSource
February 17, 2026IPO filing, Form S-1—IPO filingsSource
February 12, 2026Stake report, Schedule 13G, by Ardsley Advisory Partners LP7.76% of the class5%+ stakesSource
December 3, 2025IPO filing, Form S-1—IPO filingsSource
September 26, 2025IPO filing, Form S-1/A—IPO filingsSource

Selling to them or working with them? See who runs Aspire Biopharma Holdings, Inc. now and the warning signs.

Watch Aspire Biopharma Holdings, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Aspire Biopharma Holdings, Inc. and the records around it.

Aspire Biopharma Holdings, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Aspire Biopharma Holdings, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Aspire Biopharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Aspire Biopharma Holdings, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 16 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-12OutDirector8-K, 2026-02-12
2026-01-13Out8-K, 2026-01-13

Why did they leave? What the filings say

For each named departures below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Aspire Biopharma Holdings, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Aspire Biopharma Holdings, Inc.?

New leaders reset buying decisions — get the Full Report on Aspire Biopharma Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Aspire Biopharma Holdings, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Aspire Biopharma Holdings, Inc., with the record behind each one.

Find candidates like Director at Aspire Biopharma Holdings, Inc.

Every change, in the filing's words

Filed 2026-02-12 · 8-K

Departing: Donald G. Fell, Director

On February 6, 2026, Donald G. Fell resigned from the Aspire Biopharma Holdings, Inc.'s ("the Company") board of directors (the "Board").

Also stated in this filing

  • In connection with this transition, and the resignation of Suren Ajjarapu Philip Balatsos has been appointed to fill one of the vacancies on the Board of Directors left by the aforementioned resignations.
  • Philip Balatsos Philip Balatsos is a Senior financial markets executive with experience in foreign exchange and emerging market sales and trading.
  • He has a proven track record of driving revenue growth, expanding institutional client relationships, and building businesses across global markets.
  • His experience spans bulge-bracket banks, international financial institutions, entrepreneurial ventures, and public company boards.
  • He is presently holds a senior position at Oscar Gruss & Son Inc. in foreign exchange sales and trading.
  • He previously served as vice president of foreign exchange and emerging markets rates sales and trading at XP Investments US LLC and was the director of foreign exchange hedge fund sales at Barclays Capital.
  • He currently serves on the Board of Directors of Ciso Global, Inc. and Inspire Veterinary Partners, Inc. (OTCMKTS: IVPR), and served on the Board of Directors of Sadot Group Inc. from October 2019 through December 2023.
  • He earned his Bachelor of Science in business administration from Skidmore College.
Filed 2026-01-13 · 8-K

Departing: Surendra Ajjarapu

On January 7, 2026, Surendra Ajjarapu, a Director of Aspire Biopharma Holdings, Inc. (the "Company"), notified the Board of Directors of his intention to step down from the role of Director, effective immediately.

Tools for this story

Each opens in a new tab, filled in for Aspire Biopharma Holdings, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/aspire-biopharma-holdings
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Aspire Biopharma Holdings, Inc. executive departures 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/aspire-biopharma-holdings